Contact Us | 1-800-343-7475
In this webinar, Alexandre Lucas and Benjamin Charvet discuss the development of a laboratory-developed test on the Simple Western platform for the detection of HERV-W-ENV protein, which is involved in pathologies such as multiple sclerosis and COVID-19. Denaturation to expose the antigen makes HERV-W-ENV undetectable with ELISA but has robust, reproducible quantitation on Simple Western. Developed by a partnership between Geneuro and We-Met, the test is currently being used in a Phase 2 Long COVID clinical trial.
This webinar shares the experience of bringing the immunoassay from pre-clinical to clinical development, based on the guidelines of the European Medicines Agency, and discusses the ongoing optimization phase to eventually industrialize the test.
![]() |
Alexandre Lucas, Ph.D. |
||||
Alexandre is the founder and manager of the We-Met platform and a specialist in protein biochemistry. He manages the platform and is responsible for various training courses and developments. He started in 2005 at Inserm in Chatenay-Malabry in cardiac signaling and then joined the I2MC in 2010. He then founded the We-Met platform in 2015. |
|||||
![]() |
Benjamin Charvet, Ph.D. Senior Scientist Geneuro |
||||
|
|||||